TCS BPS Fresher Hiring for 2022 year of passing (YoP) graduates -Apply Now

bout TCS BPS Fresher Hiring for 2022 year of passing (YoP) graduates
TCS has curated exclusive opportunities for Arts, Commerce & Science graduates from the 2022 year of passing to apply for exciting careers and make #TheBigMove

REGISTRATION END DATE

7^th January 2022

TEST DATE

26th January 2022

INTERVIEW DATE

To be announced post test results

Exceptional performers will be part of TCS’ fastest growing units – Cognitive Business Operations (CBO), Banking and Financial Services and Insurance (BFSI), and Life Sciences in various enriching roles that amplify their career growth.

Application Process for TCS BPS Fresher Hiring – YoP 2022
Mandatory steps to register for TCS BPS Fresher Hiring:

Step 1. Logon to the TCS Next Step Portal here

Step 2. Register and apply for the TCS BPS Fresher Hiring process. Kindly click on Register Now, choose category as ‘BPS’ and proceed to fill your details.

Step 3. Submit your application form

For step-by-step guide, Click here

Click here to take the Mock Test and prepare better for the TCS BPS Fresher Hiring Test

APPLY NOW ON OFFICIAL PORTAL

Important Note:

You must have all your original academic documents as applicable (Till fifth semester marksheets)
Communication related to the Test will be shared with you on your registered email ID from TCS iON
TCS does not send job offers / any hiring related communication from unofficial email ids like Gmail, Rediff mail, Yahoo Mail, Hotmail etc.
TCS does not ask candidates to deposit any money for job offers
TCS is not associated with any external agency / company to conduct any interviews or make offers of employment on its behalf

Helpdesk:

For any assistance, please reach out to our TCS Helpdesk Team. Email ID: CBOCampus.support1@tcs.com | Helpdesk number: 022-67784065

• Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 24, 2025
  Hyderabad, India & Reykjavik, Iceland — Alvotech (NASDAQ: ALVO), a global biotech… Read more: Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
• Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to
  Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell CarcinomaJune 24, 2025
  Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company, launched TEVIMBRA® (tislelizumab)… Read more: Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to <br>Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma